Trial Profile
The effect of ondansetron, a 5-HT(3) receptor antagonist, in chronic fatiguesyndrome: a randomized controlled trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Chronic fatigue syndrome
- Focus Therapeutic Use
- 05 Mar 2010 New trial record
- 02 Feb 2009 Primary endpoint 'Sickness Impact Profile' has not been met.